Table 1 Changes in blood pressure, low-density lipoprotein cholesterol, antihypertensive and hypolipidemic treatment during study follow-up
Visit I (baseline) (n = 1015) | Visit II (3 months) (n = 1015) | Visit III (6 months) (n = 1015) | P value | |
|---|---|---|---|---|
SBP [mmHg] | 139 ± 16 | 136 ± 12 | 133 ± 14 | < 0.001 |
DBP [mmHg] | 84 ± 9 | 82 ± 8 | 80 ± 10 | < 0.001 |
Hypolipidemic drugs [n (%)] | ||||
Statins | 605 (59.6%) | 609 (61.8%) | 596 (60.7%) | NS |
Fenofibrate | 53 (5.2%) | 59 (6.0%) | 58 (5.9%) | NS |
Ezetimibe | 89 (8.8%) | 96 (9.7%) | 96 (9.8%) | NS |
Omega-3 lipid mediators | 64 (6.3%) | 62 (6.3%) | 60 (6.1%) | NS |
Other | 3 (0.3%) | 3 (0.3%) | 3 (0.3%) | NS |
Antihypertensive drugs [n (%)] | ||||
Calcium channel blockers | 399 (39.3%) | 392 (39.8%) | 386 (39.3%) | NS |
Diuretic | 372 (36.7%) | 371 (37.7%) | 372 (37.9%) | NS |
Angiotensin receptor blockers | 245 (24.1%) | 239 (24.3%) | 235 (23.9%) | NS |
Angiotensin II receptor blockers | 381 (37.5%) | 379 (38.5%) | 371 (37.8%) | NS |
Beta blockers | 225 (22.2%) | 221 (22.4%) | 218 (22.2%) | NS |